GleamWall
中文EN

USNA USANA HEALTH SCIENCES INC

Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 896264 · Fiscal year ends 01/03

Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.8%
TTM net income YoY-224.8%
TTM EPS YoY-226.7%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR—

Margins

Gross margin77.3%
Operating margin-0.4%
Net margin-2.3%
FCF margin3.3%
EBITDA margin3.2%

Returns

ROE-4.0%
ROA-3.0%
ROIC (approx.)-0.8%
Asset turnover1.26x

Leverage & solvency

Liabilities / assets19.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-9.35x

Cash quality & payout

Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-10-032026Q22026-07-042026Q12026-04-042025Q4*2026-01-032025Q32025-09-272025Q22025-06-282025Q12025-03-292023Q4*2024-12-28
Income statement
Revenue$205.88M$223.27M$250.22M$226.20M$213.67M$235.85M$249.54M$213.61M
Cost of revenue$48.72M$48.34M$59.44M$49.41M$48.81M$50.18M$52.45M$38.55M
Gross profit$157.17M$174.93M$190.78M$176.79M$164.85M$185.66M$197.09M$175.06M
SG&A expense$86.73M$82.32M$88.25M$78.08M$85.95M$81.91M$91.44M$73.35M
Operating income-$1.45M-$20.00M$13.87M$3.82M$1.22M$16.72M$15.67M$8.21M
Interest expense$38,000$0$240,000$123,000$49,000$259,000$411,000$129,000
Pretax income-$804,000-$18.90M$15.46M$4.18M$1.79M$18.82M$16.74M$10.43M
Income tax$6.09M$9.05M$8.51M$5.77M$8.46M$8.37M$7.45M$5.95M
Net income-$5.56M-$21.38M$7.51M-$1.77M-$6.52M$9.65M$9.40M$4.45M
EBITDA$6.67M-$12.32M$22.15M$12.38M$9.14M$24.46M$24.01M$12.21M
EPS (basic)-0.30-1.160.41—-0.360.520.49—
EPS (diluted)-0.30-1.160.41—-0.360.520.49—
Weighted avg. shares (diluted)18.50M18.49M18.41M—18.29M18.54M19.09M—
Balance sheet
Cash & equivalents$178.91M$168.56M$162.75M$158.38M$145.35M$151.34M$179.61M$181.77M
Receivables$5.03M$3.34M$9.66M$4.29M————
Inventory$84.08M$86.34M$96.36M$102.61M$90.78M$83.27M$73.56M$69.73M
Current assets$290.24M$281.07M$294.23M$288.40M$264.06M$261.87M$281.39M$279.19M
PP&E, net$94.60M$94.27M$94.62M$94.38M$96.21M$96.53M$94.25M$94.56M
Goodwill$109.26M$109.14M$138.13M$137.96M$144.29M$144.23M$144.22M$144.17M
Intangibles$120.41M$124.61M$128.90M$133.15M$138.16M$142.75M$147.16M$151.82M
Total assets$708.47M$703.21M$738.97M$742.91M$726.59M$734.53M$746.60M$748.19M
Current liabilities$112.25M$105.67M$117.24M$128.56M$118.66M$121.62M$137.38M$139.62M
Total liabilities$138.38M$132.24M$144.18M$156.64M$145.04M$148.97M$162.72M$161.86M
Shareholders' equity$526.76M$526.31M$543.55M$533.10M$528.07M$531.06M$529.76M$532.11M
Shares outstanding18.48M18.46M18.46M18.28M18.27M18.26M18.79M19.06M
Cash flow statement
Operating cash flow$11.96M$23.32M$9.76M-$3.39M-$1.96M$12.22M$15.48M$5.79M
Capital expenditure$3.52M$3.15M$2.65M$2.79M$3.20M$5.03M$2.80M$1.80M
Free cash flow$8.44M$20.16M$7.11M-$6.18M-$5.16M$7.19M$12.68M$3.98M
Investing cash flow-$3.52M-$4.06M-$2.60M$1.11M-$3.20M-$4.16M-$3.88M-$205.14M
Financing cash flow-$92,000-$14.03M-$3.64M$13.45M-$979,000-$38.61M-$14.47M$22.93M
Depreciation & amortization$8.12M$7.67M$8.28M$8.56M$7.92M$7.74M$8.34M$4.00M
Stock-based compensation$3.40M$3.40M$3.45M$3.75M$3.58M$3.62M$2.88M$3.61M
Share buybacks$0$0$0$0$0$15.21M$12.30M$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.